Driven by its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen is creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Vaxcyte
5 followers
Enveda Biosciences
2 followers
Immunome
2 followers
Paradromics
2 followers
Protara Therapeutics
2 followers
Cogent Biosciences
1 follower
Cue Biopharma
1 follower
Centessa Pharmaceuticals
3 followers
Enliven Therapeutics
1 follower
Thermo Fisher Scientific
284 followers
Genentech
226 followers
Gilead Sciences
213 followers